小儿肺咳颗粒辅助治疗儿童急性下呼吸道感染的Meta分析
结果显示联合治疗可提高临床有效率、缩短咳嗽、啰音、发热、炎症病灶消失时间及住院时间,并改善免疫炎症指标,不良事件无显著差异,但异质性和发表偏倚需谨慎解读。
要点
- 小儿肺咳颗粒联合常规药物可提高儿童ALRI临床有效率。
- 联合治疗可缩短咳嗽、啰音、发热、炎症病灶消失时间及住院时间。
- 不良事件无显著增加,但证据受异质性和发表偏倚限制。
核心结论
- Meta分析结果支持小儿肺咳颗粒用于儿童急性下呼吸道感染的治疗。
- 因现有数据存在显著异质性和发表偏倚,结论需谨慎对待,仍需高质量RCT进一步验证。
研究设计与样本
- 系统检索截至2019年7月的4个英文数据库和4个中文数据库,纳入小儿肺咳颗粒治疗ALRI的随机对照试验。
主要发现
- 小儿肺咳颗粒组临床有效率显著高于常规药物组(RR=1.17,95% CI=1.13-1.22,P<0.00001)。
- 与常规药物组相比,联合组咳嗽消失时间(MD=-1.92,95% CI=-2.33,-1.51,P<0.00001)、啰音消失时间(MD=-1.68,95% CI=-2.27,-1.10,P<0.00001)、发热消失时间(MD=-1.46,95% CI=-1.92,-1.00,P<0.00001)、炎症病灶消失时间(MD=-2.43,95% CI=-2.94,-1.93,P<0.00001)及住院时间(MD=-2.26,95% CI=-3.03,-1.49,P<0.00001)均显著缩短。
- 在细胞和分子层面,常规药物联合小儿肺咳颗粒后CD4、CD8、CD4/CD8、IL-6、TNF-α和CRP水平显著改善。
- 小儿肺咳颗粒组与常规药物组不良事件发生率无显著差异(RR=0.97,95% CI=0.61-1.54,P=0.89)。
临床怎么用
- 在常规药物治疗基础上,可考虑联合小儿肺咳颗粒以缩短儿童ALRI症状消失时间和住院时间。
- 临床应用需结合患儿具体情况,并关注现有证据的异质性和发表偏倚对结论可靠性的影响。
局限性
- 现有数据存在显著异质性。
- 存在发表偏倚。
- 需要进一步设计良好、高质量的RCT验证疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Over the past five years the Chinese herbal formula (CHF) medicine, Xiaoer-Feike granules (XFG), has become a widely used adjuvant therapy for acute lower respiratory infections (ALRI). Considering the rapid popularization and application of XFG, and the lack of systematic evidence evaluating its effectiveness and safety in treating ALRI, it is necessary to conduct a meta-analysis to determine its benefits for patients. METHODS: This study systematically identified randomized controlled trials (RCTs) of XFG treatments for ALRI through July 2019 using four English-databases (PubMed, Cochrane Library, Ovid, and Web of Science) and four Chinese-databases (Sino-med database, China National Knowledge Infrastructure (CNKI), VIP database, and the WANFANG database). We then performed a quality assessment and data analysis with Review Manager 5.3.5 and Stata 15.1. RESULTS: Twenty-one RCTs involving 3425 patients were randomly divided into an XFG group and a conventional medicine (CM) group. The results showed that the clinical efficacy rate (CER) of the XFG group was significantly higher than that of the CM group (RR=1.17, 95% CI =1.13-1.22, P< 0.00001). In comparison with the CM group, the XFG group had strikingly shortened: resolution time of cough (RTC) (MD = -1.92; 95% CI =-2.33, -1.51, P<0.00001); resolution time of rale (RTR) (MD = -1.68; 95% CI =-2.27, -1.10, P<0.00001); resolution time of fever (RTF) (MD = -1.46; 95% CI =-1.92, -1.00, P<0.00001); resolution time of inflammatory lesions (RTIL) (MD = -2.43, 95% CI =-2.94, -1.93, P< 0.00001); and hospital stays (HS) (MD = -2.26, 95% CI =-3.03, -1.49, P< 0.00001). At the cellular and molecular level, the CD4, CD8, CD4/CD8, IL-6, TNF-α, and CRP levels were significantly improved when CM was complemented with XFG. In addition, no significant difference was observed between the XFG and CM groups in terms of the adverse events (AE) (RR =0.97, 95% CI= 0.61-1.54, P= 0.89). CONCLUSIONS: The findings of this meta-analysis support the use of XFG in the treatment of ALRI. However, these results should be treated with caution due to the significant heterogeneity and publication bias of existing data. Further well-designed and high-quality RCTs are needed to interrogate the efficacy and safety of XFG.
引用
- You Q, Li L, Li D, et al. Meta-Analysis on the Chinese Herbal Formula Xiaoer-Feike Granules as a Complementary Therapy for Children With Acute Lower Respiratory Infections. Front Pharmacol. 2020. PMID: 33192498. doi:10.3389/fphar.2020.496348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。